Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2016

01-07-2016 | Original Article

Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients

Authors: John Gubatan, Kyle Staller, Kenneth Barshop, Braden Kuo

Published in: Digestive Diseases and Sciences | Issue 7/2016

Login to get access

Abstract

Background

The role of cannabinoids in gastrointestinal diseases is controversial and of great interest, yet their use in patients has not been critically examined.

Aim

To determine the prevalence and effects of cannabis abuse on healthcare utilization, as measured by emergency department (ED) visits, in a large, tertiary gastroenterology practice.

Methods

All patients seen in the gastroenterology clinic at a tertiary care center during a 27-year period (1986–2013) were included in our study to determine the overall prevalence of cannabis abuse. We matched cannabis abusers 1:2 with non-abusing controls to determine the effect of cannabis on ED utilization, our primary outcome. We used multivariate linear regression to adjust for confounders and define the independent effect of cannabis abuse on ED utilization.

Results

Our prevalence study cohort included 190,303 GI clinic patients with an overall cannabis abuse prevalence of 0.80 % (1520 patients). From 1986 to 2012, the prevalence of cannabis abuse in this clinic increased by 0.73 % (0.03 %/year) (p < 0.0001). From the 1520 cannabis abusers identified, 467 patients were randomly selected as cases and were matched to 934 controls. From this retrospective cohort, the median ED visits/year for cannabis abusers was 1.88 versus 0.89 for non-abusers (p < 0.0001). After multivariate adjustment, cannabis abuse was associated with a 1.47-fold increase (95 % CI 1.23–1.76, p < 0.0001) in median ED visits/year.

Conclusions

Reported cannabis abuse in GI clinic patients is less prevalent than in the adult US population, but is increasing. Cannabis abuse among gastroenterology patients is associated with increased ED visits.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cerdá M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120:22–27.CrossRefPubMed Cerdá M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120:22–27.CrossRefPubMed
3.
go back to reference Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89–97.CrossRefPubMed Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89–97.CrossRefPubMed
4.
go back to reference Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293:795–797.CrossRefPubMed Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293:795–797.CrossRefPubMed
5.
go back to reference McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol. 2007;152:583–593.CrossRefPubMedPubMedCentral McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol. 2007;152:583–593.CrossRefPubMedPubMedCentral
6.
go back to reference Pertwee RG. Pharmacology of cannabinoid CB 1 and CB 2 receptors. Pharmacol Ther. 1997;74:129–180.PubMed Pertwee RG. Pharmacology of cannabinoid CB 1 and CB 2 receptors. Pharmacol Ther. 1997;74:129–180.PubMed
7.
go back to reference Coruzzi G, Adami M, Coppelli G, Frati P, Soldani G. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedeberg’s Arch Pharmacol. 1999;360:715–718.CrossRef Coruzzi G, Adami M, Coppelli G, Frati P, Soldani G. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedeberg’s Arch Pharmacol. 1999;360:715–718.CrossRef
8.
go back to reference Germanò MP, D’Angelo V, Mondello MR, et al. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedeberg’s Arch Pharmacol. 2001;363:241–244.CrossRef Germanò MP, D’Angelo V, Mondello MR, et al. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedeberg’s Arch Pharmacol. 2001;363:241–244.CrossRef
9.
go back to reference Izzo AA, Mascolo N, Capasso R, Germanò MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedeberg’s Arch Pharmacol. 1999;360:221–223.CrossRef Izzo AA, Mascolo N, Capasso R, Germanò MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedeberg’s Arch Pharmacol. 1999;360:221–223.CrossRef
10.
go back to reference Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134:563–570.CrossRefPubMedPubMedCentral Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134:563–570.CrossRefPubMedPubMedCentral
11.
go back to reference Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–270.CrossRefPubMed Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–270.CrossRefPubMed
12.
go back to reference Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154:1001–1008.CrossRefPubMedPubMedCentral Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154:1001–1008.CrossRefPubMedPubMedCentral
13.
go back to reference Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2007;293:G137–G145.CrossRefPubMed Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2007;293:G137–G145.CrossRefPubMed
14.
go back to reference Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed
15.
go back to reference Naftali T, Schleider LBL, Dotan I, Lansky EP, Benjaminov FS, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.CrossRefPubMed Naftali T, Schleider LBL, Dotan I, Lansky EP, Benjaminov FS, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.CrossRefPubMed
16.
go back to reference Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2011;85:1–8.CrossRefPubMed Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2011;85:1–8.CrossRefPubMed
17.
go back to reference Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141:1638–1647.CrossRefPubMedPubMedCentral Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141:1638–1647.CrossRefPubMedPubMedCentral
18.
go back to reference Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72:1235–1242.CrossRefPubMed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72:1235–1242.CrossRefPubMed
19.
go back to reference Gieringer DH. The acceptance of medicinal marijuana in the US. J Cannabis Ther. 2003;3:53–65.CrossRef Gieringer DH. The acceptance of medicinal marijuana in the US. J Cannabis Ther. 2003;3:53–65.CrossRef
20.
go back to reference Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a research patient data repository. In AMIA Annual Symposium of Proceedings; 2006: 1044. Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a research patient data repository. In AMIA Annual Symposium of Proceedings; 2006: 1044.
22.
go back to reference Budney AJ. Are specific dependence criteria necessary for different substances: How can research on cannabis inform this issue? Addiction. 2006;101:125–133.CrossRefPubMed Budney AJ. Are specific dependence criteria necessary for different substances: How can research on cannabis inform this issue? Addiction. 2006;101:125–133.CrossRefPubMed
23.
go back to reference Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 1998;10:255–264.CrossRefPubMed Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 1998;10:255–264.CrossRefPubMed
24.
go back to reference Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97:2290–2299.CrossRefPubMed Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97:2290–2299.CrossRefPubMed
25.
go back to reference Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986–1993.CrossRefPubMed Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986–1993.CrossRefPubMed
26.
go back to reference de Boer AG, Sprangers MA, Bartelsman JF, de Haes HC. Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. Eur J Gastroenterol Hepatol. 1998;10:783–790.CrossRefPubMed de Boer AG, Sprangers MA, Bartelsman JF, de Haes HC. Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. Eur J Gastroenterol Hepatol. 1998;10:783–790.CrossRefPubMed
27.
go back to reference Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol. 2001;96:1340–1349.CrossRefPubMed Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol. 2001;96:1340–1349.CrossRefPubMed
28.
go back to reference Hillilä MT, Siivola MT, Färkkilä MA. Comorbidity and use of health-care services among irritable bowel syndrome sufferers. Scand J Gastroenterol. 2007;42:799–806.CrossRefPubMed Hillilä MT, Siivola MT, Färkkilä MA. Comorbidity and use of health-care services among irritable bowel syndrome sufferers. Scand J Gastroenterol. 2007;42:799–806.CrossRefPubMed
29.
go back to reference Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend. 2001;64:319–327.CrossRefPubMed Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend. 2001;64:319–327.CrossRefPubMed
30.
go back to reference von Sydow K, Lieb R, Pfister H, Höfler M, Sonntag H, Wittchen HU. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend. 2001;64:347–361.CrossRef von Sydow K, Lieb R, Pfister H, Höfler M, Sonntag H, Wittchen HU. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend. 2001;64:347–361.CrossRef
31.
go back to reference Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006.
32.
go back to reference Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse. 2002;28:643–652.CrossRefPubMed Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse. 2002;28:643–652.CrossRefPubMed
33.
go back to reference Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1749.CrossRefPubMed Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1749.CrossRefPubMed
34.
go back to reference Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.CrossRefPubMed Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.CrossRefPubMed
35.
go back to reference Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007.CrossRefPubMed Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007.CrossRefPubMed
36.
go back to reference Best WR. Predicting the Crohn’s disease activity index from the Harvey bradshaw index. Inflamm Bowel Dis. 2006;12:304–310.CrossRefPubMed Best WR. Predicting the Crohn’s disease activity index from the Harvey bradshaw index. Inflamm Bowel Dis. 2006;12:304–310.CrossRefPubMed
37.
go back to reference Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–976.PubMed Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–976.PubMed
38.
go back to reference Fuster D, Cheng DM, Allensworth-Davies D, Palfai TP, Samet JH, Saitz R. No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use. J Gen Intern Med. 2014;29:133–139.CrossRefPubMed Fuster D, Cheng DM, Allensworth-Davies D, Palfai TP, Samet JH, Saitz R. No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use. J Gen Intern Med. 2014;29:133–139.CrossRefPubMed
40.
go back to reference Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174:1668–1673.CrossRefPubMedPubMedCentral Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174:1668–1673.CrossRefPubMedPubMedCentral
41.
go back to reference Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231–244.CrossRefPubMed Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231–244.CrossRefPubMed
42.
go back to reference Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002;40:675–685.CrossRefPubMed Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002;40:675–685.CrossRefPubMed
44.
go back to reference Lemstra M, Bennett NR, Neudorf C, et al. A meta-analysis of marijuana and alcohol use by socio-economic status in adolescents aged 10–15 years. Can J Public Health. 2008;99(3):172–177.PubMed Lemstra M, Bennett NR, Neudorf C, et al. A meta-analysis of marijuana and alcohol use by socio-economic status in adolescents aged 10–15 years. Can J Public Health. 2008;99(3):172–177.PubMed
46.
go back to reference Patrick ME, Wightman P, Schoeni RF, Schulenberg JE. Socioeconomic status and substance use among young adults: a comparison across constructs and drugs. J Stud Alcohol Drugs. 2012;73:772–782.CrossRefPubMedPubMedCentral Patrick ME, Wightman P, Schoeni RF, Schulenberg JE. Socioeconomic status and substance use among young adults: a comparison across constructs and drugs. J Stud Alcohol Drugs. 2012;73:772–782.CrossRefPubMedPubMedCentral
47.
go back to reference Gerich ME, Isfort RW, Brimhall B, Siegel CA. Medical marijuana for digestive disorders: High time to prescribe? Am J Gastroenterol. 2015;110:208–214.CrossRefPubMed Gerich ME, Isfort RW, Brimhall B, Siegel CA. Medical marijuana for digestive disorders: High time to prescribe? Am J Gastroenterol. 2015;110:208–214.CrossRefPubMed
Metadata
Title
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients
Authors
John Gubatan
Kyle Staller
Kenneth Barshop
Braden Kuo
Publication date
01-07-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4090-9

Other articles of this Issue 7/2016

Digestive Diseases and Sciences 7/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.